BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings

20.10.25 12:50 Uhr

Werte in diesem Artikel

FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. The BD Incada™ Platform is available now with the launch of the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution, creating enterprise-wide visibility and connectivity that transforms data into actionable insight.  

BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings

"Our vision for the BD Incada™ Platform is to go beyond legacy connectivity to create meaningful connections across devices from infusion pumps to patient monitors to pharmacy robotics, and unify data from those solutions into one ecosystem, transforming data into clear, actionable insights for care teams," said Bilal Muhsin, EVP and President of BD Connected Care. "These launches represent key milestones in BD's Connected Care strategy, where we are uniquely positioned with our broad portfolio from pharmacy to bedside, to leverage game-changing technology to drive meaningful benefits for our customers."

AI-powered analytics to drive smarter, faster decisions

Built on Amazon Web Services' (AWS) on-demand cloud computing infrastructure, the BD Incada™ Platform leverages the latest in AI technologies, such as natural language search in analytics, and is scalable to meet the data volumes created by nearly 3 million smart connected BD devices. With Analytics in the BD Incada™ Platform, data from BD's leading medication management solutions now flows through a secure, cloud platform and enables:

  • Enterprise-wide visibility into medication inventory, which helps clinicians identify patterns and ensure medication availability, reduce medication waste and improve labor efficiency
  • The ability to ask natural language questions and receive AI-powered insights and analytics on demand
  • User-customizable dashboards that empower frontline clinical teams to act on insights quickly

Flexible, secure storage to get the right medication to the right patient, faster

The new BD Pyxis™ Pro Dispensing Solution delivers smarter, more secure medication storage, which enables faster access at the point of care. The first-of-its-kind flexible, stackable device configuration offers more medication storage capacity to improve medication availability from refrigerated to ambient storage. The BD Pyxis™ Pro Dispensing Solution allows hospitals and health systems to easily adapt to the evolving needs of their patient populations, with features including:

  • Expanded capacity in a similar footprint, enabling clinicians to add up to 538 multi-access or 98 secure pockets without taking more space in their medication rooms
  • Enhanced security features to improve controlled substance management and medication safety efforts
  • More efficient access, with RFID badge scanning, wireless barcode scanners and illuminated bins to streamline medication retrieval

"For over 35 years, the BD Pyxis™ System has been the backbone of medication management across hospitals and health systems, with more than 9.8 million transactions on BD Pyxis™ devices every day," said Connor Bates, Worldwide President for Medication Management Solutions at BD. "With the enhanced secure capacity, durability and AI-powered analytics of the next-generation BD Pyxis™ Pro Dispensing Solution, we're ushering in a transformative new era for medication management."

Together, the BD Incada™ Platform and BD Pyxis™ Pro Dispensing Solution sets a new standard for unified, data-driven healthcare operations.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiency, improve safety, and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Contacts:
                                                            


Media

Investors:

Fallon McLoughlin                                                   

Adam Reiffe

Director, Public Relations                                         

VP, Investor Relations

201.258.0361                                                           

201.847.6927

fallon.mcloughlin@bd.com                                       

adam.reiffe@bd.com       

 

BD (Becton, Dickinson and Company) Logo (PRNewsfoto/BD (Becton, Dickinson and Company))

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-launches-new-ai-enabled-solutions-to-drive-connectivity-across-healthcare-settings-302588426.html

SOURCE BD (Becton, Dickinson and Company)

In eigener Sache

Übrigens: Becton, Dickinson und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Becton, Dickinson

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Becton, Dickinson

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Becton, Dickinson & Co. (BD)

Wer­bung

Analysen zu Becton, Dickinson & Co. (BD)

DatumRatingAnalyst
13.05.2019Becton, DickinsonCo (BD) OverweightBarclays Capital
07.12.2018Becton, DickinsonCo (BD) BuyDeutsche Bank AG
16.10.2018Becton, DickinsonCo (BD) Equal WeightBarclays Capital
09.03.2018Becton, DickinsonCo (BD) Market PerformBMO Capital Markets
29.12.2017Becton, DickinsonCo (BD) BuyDeutsche Bank AG
DatumRatingAnalyst
13.05.2019Becton, DickinsonCo (BD) OverweightBarclays Capital
07.12.2018Becton, DickinsonCo (BD) BuyDeutsche Bank AG
09.03.2018Becton, DickinsonCo (BD) Market PerformBMO Capital Markets
29.12.2017Becton, DickinsonCo (BD) BuyDeutsche Bank AG
19.08.2015Becton, DickinsonCo (BD) BuyArgus Research Company
DatumRatingAnalyst
16.10.2018Becton, DickinsonCo (BD) Equal WeightBarclays Capital
03.11.2017Becton, DickinsonCo (BD) Sector PerformRBC Capital Markets
09.05.2016Becton, DickinsonCo (BD) Sector PerformRBC Capital Markets
10.08.2015Becton, DickinsonCo (BD) HoldDeutsche Bank AG
07.08.2015Becton, DickinsonCo (BD) Sector PerformRBC Capital Markets
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Becton, Dickinson & Co. (BD) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen